Study S003197

Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07503210
Acronym: AMAZE 12
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 606
Start: 2026-04-21
Primary completion: 2028-06-06
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1327-1477; OTHER:2025-523804-62; NIH:2025

Registered primary outcomes

Relative change in body weight [From week 40 to week 92]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.